April 2 (Reuters) - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...
AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...
AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad ...
AstraZeneca reported mixed phase 3 data for efzimfotase alfa in hypophosphatasia, with positive results in paediatric ...
Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
AstraZeneca ( (GB:AZN) ) has shared an announcement.
A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...
The COVID-19 pandemic and the growing burden of non-communicable diseases (NCDs) have compelled healthcare stakeholders to explore new ways of improving health systems, stimulating the advancement of ...
AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.
AstraZeneca (www.AstraZeneca.com) is pleased to announce its partnership with MYDAWA as part of our commitment to work towards a future where all people have access to sustainable healthcare solutions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results